Disease-A-Month
Volume 52, Issue 9 , Pages 343-362 , September 2006

Osteoarthritis

  • Gina Gill Glass, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Gina Gill Glass, MD, 216 Sherbrooke Dr., Newport News, VA 23602

References 

  1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41:778–799
  2. CDC. Prevalence of disabilities and associated health conditions among adults: United States, 1999. MMWR. 2001;50:120–125
  3. Sinkov V, Cymet T. Osteoarthritis: understanding the pathophysiology, genetics, and treatments. J Natl Med Assoc. 2003;95:475–482
  4. Fife R. Osteoarthritis: A. Epidemiology, pathology and pathogenesis. In:  Klippel JH editors. Primer on the rheumatic diseases. 11th edition. Atlanta: The Arthritis Foundation; 1997;p. 216–217
  5. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage. 2004;12(Suppl A):S31–S33
  6. Hochberg M. Osteoarthritis: B. Clinical features and treatment. In:  Klippel JH editors. Primer on the rheumatic diseases. 11th edition. Atlanta: The Arthritis Foundation; 1997;p. 218–221
  7. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update (American College of Rheumatology Subcommittee on Osteoarthritis Guidelines). Arthritis Rheum. 2000;43:1905–1915
  8. Fransen M, McConnell S, Bell M. Exercise for osteoarthritis of the hip or knee. In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley and Sons; 2004;
  9. Scott D, Smith C, Lohmander S, et al. Osteoarthritis. Clin Evid. 2004;11:1560–1588
  10. Felson DT. Does excess weight cause osteoarthritis and, if so, why?. Ann Rheum Dis. 1996;55:668–670
  11. Nevitt MC. Obesity outcomes in disease management: clinical outcomes for osteoarthritis. Obes Res. 2002;10(Suppl 1):33S–37S
  12. Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women (The Framingham Study). Ann Intern Med. 1992;116:535–539
  13. Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum. 2004;50:1501–1510
  14. Brosseau L, Yonge KA, Robinson V, et al. Thermotherapy for treatment of osteoarthritis. In: The Cochrane Library, issue 3. Chichester, UK: John Wiley and Sons; 2004;
  15. Cushnaghan J, McCarthy C, Dieppe P. Taping the patella medially: a new treatment for osteoarthritis of the knee joint?. BMJ. 1994;308:753–755
  16. Toda Y, Segal N. Usefulness of an insole with subtalar strapping for analgesia in patients with medial compartment osteoarthritis of the knee. Arthritis Rheum. 2002;47:468–473
  17. Toda Y, Segal N, Kato A, et al. Correlation between body composition and efficacy of lateral wedged insoles for medial compartment osteoarthritis of the knee. J Rheumatol. 2002;29:541–545
  18. Toda Y, Segal N, Kato A, et al. Effect of a novel insole on the subtalar joint of patients with medial compartment osteoarthritis of the knee. J Rheumatol. 2001;28:2705–2710
  19. Maillefert JF, Hudry C, Baron G, et al. Laterally elevated wedged insoles in the treatment of medial knee osteoarthritis: a prospective randomized controlled study. Osteoarthritis Cartilage. 2001;9:738–745
  20. Ezzo J, Hadhazy V, Birch S, et al. Acupuncture for osteoarthritis of the knee: a systematic review. Arthritis Rheum. 2001;44:819–825
  21. Hulme J, Robinson V, DeBie R, et al. Electromagnetic fields for the treatment of osteoarthritis. In: The Cochrane Library, issue 3. Chichester, UK: John Wiley and Sons; 2004;
  22. Wolsko PM, Eisenberg DM, Simon LS, et al. Double-blind placebo-controlled trial of static magnets for the treatment of osteoarthritis of the knee: results of a pilot study. Altern Ther Health Med. 2004;10:36–43
  23. Superio-Cabuslay E, Ward MM, Lorig KR. Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory drug treatment. Arthritis Care Res. 1996;9:292–301
  24. Barlow JH, Turner AP, Wright CC. A randomized controlled study of the Arthritis Self-Management Programme in the UK. Health Educ Res. 2000;15:665–680
  25. Solomon DH, Warsi A, Brown-Stevenson T, et al. Does self-management education benefit all populations with arthritis? (A randomized controlled trial in a primary care physician network). J Rheumatol. 2002;29:362–368
  26. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? (A meta-analysis of randomised controlled trials). Ann Rheum Dis. 2004;63:901–907
  27. Towheed TE, Judd MJ, Hochberg MC, et al. Acetaminophen for osteoarthritis. In: The Cochrane Library, issue 3. Chichester, UK: John Wiley and Sons; 2004;
  28. Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum. 2004;51:746–754
  29. Towheed T, Shea B, Wells G, et al. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev. 1997;4:CD000517
  30. Watson MC, Brookes ST, Kirwan JR, et al. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev. 1997;1:CD000142
  31. Gotzche P. Non-steroidal anti-inflammatory drugs. Clin Evid. 2004;11:1551–1559
  32. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325:619–623
  33. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996;312:1563–1566
  34. Richy F, Bruyere O, Ethgan O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004;63:759–766
  35. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959
  36. Merck announces voluntary worldwide withdrawal of Vioxx. Available at: www.merck.com/newsroompress_releases/product/200_0930.html. Accessed November 6, 2004.
  37. Rostrum A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. In: The Cochrane Library, issue 3. Chichester, UK: John Wiley & Sons; 2004;
  38. Hooper L, Brown TJ, Elliott RA, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329:948
  39. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin: a meta-analysis. Eur J Clin Pharmacol. 1994;46:517–522
  40. Towheed TE, Anastassiades TP, Shea B, et al. Glucosamine therapy for treating osteoarthritis. In: The Cochrane Library, issue 3. Chichester, UK: John Wiley and Sons; 2004;
  41. McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283:1469–1475
  42. Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162:2113–2123
  43. Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27:205–211
  44. Soeken KL, Lee WL, Bausell RB, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. 2002;51:425–430
  45. Najm WI, Reinsch S, Hoehler F, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord. 2004;5:6
  46. Little CV, Parsons T. Herbal therapy for treating osteoarthritis. In: The Cochrane Library, issue 3. Chichester, UK: John Wiley and Sons; 2004;
  47. Long L, Soeken K, Ernst E. Herbal medicines for the treatment of osteoarthritis: a systematic review. Rheumatology (Oxford). 2001;40:779–793
  48. Ernst E. The efficacy of Phytodolor for the treatment of musculoskeletal pain: a systematic review of randomized clinical trials. Natur Med Online. 2000;3:
  49. Kjaersgaard-Andersen P, Nafei A, Skov O, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip: a randomized, double-blind, multi-centre study. Pain. 1990;43:309–318
  50. Quiding H, Grimstad J, Rusten K, et al. Ibuprofen plus codeine, ibuprofen, and placebo in a single- and multidose cross-over comparison for coxarthrosis pain. Pain. 1992;50:303–307
  51. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000;160:853–860
  52. Lipman AG. Treatment of chronic pain in osteoarthritis: do opioids have a clinical role?. Curr Rheumatol Rep. 2001;3:513–519
  53. Katz WA. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs. 1996;52(Suppl 3):39–47
  54. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. 1998;25:1358–1363
  55. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 1999;42:1370–1377
  56. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage. 2004;28:59–71
  57. Jordan KM, Arden NK, Doherty M, et al. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145–1155
  58. Espallargues M, Pons JM. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis: a systematic review. Int J Technol Assess Health Care. 2003;19:41–56
  59. American Academy of Orthopaedic Surgeons. AAOS clinical guideline on osteoarthritis of the knee (phase II). Rosemont (IL): American Academy of Orthopaedic Surgeons; 2003;p. 15
  60. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2004;[epub ahead of print]
  61. Moseley JB, O’Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347:81–88
  62. Gidwani S, Fairbank A. The orthopaedic approach to managing osteoarthritis of the knee. BMJ. 2004;329:1220–1224
  63. Ethgen O, Bruyere O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. J Bone Joint Surg Am. 2004;86-A:963–974

PII: S0011-5029(06)00084-8

doi: 10.1016/j.disamonth.2006.09.001

Disease-A-Month
Volume 52, Issue 9 , Pages 343-362 , September 2006

Article Tools